|
Temozolomide is an oral alkylating agent used for the treatment of Grade IV astrocytoma-an aggressive brain tumor, also known as glioblastoma multiforme-as well as for treating melanoma, a form of skin cancer. Temozolomide is also indicated for relapsed Grade III anaplastic astrocytoma and not indicated for, but as of 2011 used to treat oligodendroglioma brain tumors in some countries, replacing the older PCV (Procarbazine-Lomustine-Vincristine) regimen. The story of temozolomide(CAS NO.:85622-93-1) starts in the late 1970s in Birmingham, where Professor Stevens was leading a team of researchers at Aston University. Building on the earlier work of pioneering Cancer Research UK scientist, Professor Tom Connors, they were carrying out innovative lab experiments to develop new drug prototypes and test their potential against cancer. It took almost a decade of painstaking work and rigorous testing in the lab, but by 1987 they’d made a new molecule that looked like a promising candidate. Initially known by the unattractive moniker CCRG81045, this was gradually developed, step by step, into what we now call temozolomide."I don't think there was ever a Eureka' hats-in-the-air moment," said Professor Stevens. "There was no particular moment in time when temozolomide was ‘discovered' ". In fact, he says, all of the work he did-as a PhD student, and as lecturer at Edinburgh University-contributed to the drug’s development.But, says Stevens, it was funding from Cancer Research UK (then known as the Cancer Research Campaign) that was vital, allowing the team to push forward with developing their new compounds, without pressing commercial or legal interests. Earlier in the 1980s, we formed our Phase I/II Clinical Trials Committee, the forerunner to our Drug Development Office. The committee’s aim was simple-to improve the transition of potential new cancer treatments from the lab to patients for testing in trials. At the time, the Clinical Trials Committee didn't have many new cancer drugs to work with, so they were eager to find potential treatments to bring forward. Professor Stevens's exciting work convinced the Committee to set up the first ever trial of temozolomide in a small group of cancer patients at Charing Cross Hospital in London. The results of this early-stage trial were very promising, encouraging Cancer Research UK to support further clinical trials in larger groups. But larger trials brought an additional challenge to be overcome. Temozolomide was first produced in the relatively small quantities needed for lab work at Aston University. Once clinical trials started, demand for the drug increased dramatically. Thankfully, the researchers at our Formulation Unit at the University of Strathclyde were at hand. They developed a process to make bigger batches of temozolomide. And they manufactured and supplied the drug in capsules to treat patients in clinical trials. Want to learn more information about temozolomide, you can access the guidechem.com. Guidechem.com is just a place for you to look for some chemicals. Guidechem provide the most convenient conditions for the international buyers and let these leads benefit all the business people.
Related Articles -
Temozolomide, guidechem, 85622-93-1,
| 
